The news is directly about Ascendis Pharma and is likely to have a neutral impact on its stock price in the short term. The Equal-Weight rating suggests that Morgan Stanley believes the stock is fairly valued at its current price. The maintained price target indicates that the analyst does not expect significant price movement in the near future.